Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies

Remibrutinib showed sustained efficacy and a consistent, favorable long-term safety profile in patients with CSU remaining symptomatic despite second-generation H<sub>1</sub>-antihistamines.

Authors

Institutions

Publication Details

Journal
Journal of Allergy and Clinical Immunology
Published
2025-10-18
DOI
https://doi.org/10.1016/j.jaci.2025.09.028
Citations
3
Primary Topic
Autoimmune Bullous Skin Diseases
Type
article
Field-Weighted Citation Impact
4.41
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies

Noriko Seko, Michihiro Hide, Michael Palumbo, Mark Lebwohl et al.
3 citations
Journal of Allergy and Clinical Immunology
Autoimmune Bullous Skin Diseases
4.41
article

Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies

Noriko Seko, Michihiro Hide, Michael Palumbo, Mark Lebwohl, Gordon Sussman, R. Szalewski, Vipul Jain, Bin Yang, Giselle Mosnaim, Ekin Şavk, Ana Maria Giménez‐Arnau, Sarbjit S. Saini, Artem Zharkov, Martin Metz, E.D. Martzloff, A. Khemis, Irena Walecka-Herniczek, Claire Field, Sibylle Haemmerle, Pengpeng Wang, P.G.P Machado, K. Lheritier
article en
3 citations

Abstract

Remibrutinib showed sustained efficacy and a consistent, favorable long-term safety profile in patients with CSU remaining symptomatic despite second-generation H<sub>1</sub>-antihistamines.

Journal of Allergy and Clinical ImmunologyVol. 157(1)
Novartis (Switzerland) (CH), NorthShore University HealthSystem (US), Johns Hopkins University (US), Universitat Pompeu Fabra (ES), University of Toronto (CA), Johns Hopkins Medicine (US), Humboldt-Universität zu Berlin (DE), Novartis (China) (CN), Hiroshima City Asa Citizens Hospital (JP), Novartis (Japan) (JP), Novartis (United States) (US), Probity Medical Research (CA), Central Clinical Hospital (PL), Asthma Association (BG), Allergy Associates Research Center (US), Novartis (Ireland) (IE), Southern Medical University (CN), Adnan Menderes University (TR), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 5%
Autoimmune Bullous Skin Diseases
4.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.